Skip to main content

Table 1 Univariable Cox proportional hazard analysis of relationship between clinical variables and recurrence-free survival

From: Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer

 

Recurrence-free survival

Variable

Number of patients

Number of events

P value

Hazard ratio

95 % CI

Tumor (T) stage prior to NAC

  

0.731

  

 T1

28

1

   

 T2

149

19

 

2.42

0.32, 18.16

 T3

79

12

 

2.7

0.35, 20.99

 T4

16

3

 

2.91

0.30, 28.09

Node (N) stage prior to NAC

  

0.558

  

 Negative

55

6

   

 Positive

217

29

 

1.29

0.54, 3.11

Clinical stage

  

0.847

  

 II

185

24

   

 III

86

11

 

0.93

0.46, 1.91

 Unknown

1

    

Age

  

0.008

  

 ≤50 years at diagnosis

177

17

   

 >50 years at diagnosis

95

18

 

2.49

1.28, 4.85

Menopausal status

  

0.017

  

 Premenopausal

161

15

   

 Perimenopausal

16

2

 

1.42

0.32, 6.24

 Postmenopausal

91

18

 

2.74

1.38, 5.46

 Unknown

4

    

Histologya

  

0.835

  

 Adenocarcinoma, n

18

3

   

 Ductal carcinoma

207

27

 

1.39

0.42, 4.62

 Lobular carcinoma

39

4

 

0.93

0.21, 4.16

 Other

8

1

 

1.08

0.11, 10.42

Progesterone receptora

  

0.199

  

 Negative

76

13

   

 Positive

192

21

 

0.63

0.31, 1.26

 Unknown

4

    

Tumor gradea

  

0.14

  

 Good

28

2

   

 Moderate

117

16

 

3.57

0.8, 15.93

 Poor

32

5

 

3.52

0.66, 18.73

 Unknown

95

    

Chemotherapy regimen

  

0.89

  

 ddAC

167

20

   

 AC-CD

77

8

 

1.23

0.54, 2.83

 AD

14

4

 

0.79

0.25, 2.55

 CD

13

3

 

1.33

0.39, 4.51

 Unknown

1

    

Pathologic response

     

ypT0/isypN0:

No

261

35

0.41

  
 

yes

11

0

 

0.37

0, −b

ypT0/is:

No

251

34

0.29

  
 

yes

21

1

 

0.39

0.05, 2.88

ypT < mic:

No

221

28

0.91

  
 

yes

51

7

 

0.95

0.42, 0.91

  1. Univariable Cox model for clinical and pathologic parameters of recurrence-free survival. aDetermined on pre-chemotherapy ultrasound-guided biopsy. b− CI boundary could not be estimated. NAC neoadjuvant chemotherapy, CI confidence interval , (dd)AC (dose-dense) cyclophosphamide and doxorubcin, CD capecitabine and docetaxel, AD doxorubcin and docetaxel, ypT0/isypN0 no residual invasive tumor in breast and axilla, ypT0/is no residual invasive tumor in the breast, ypT < mic few scattered tumor cells in the breast. Numbers in bold are significant values
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us